cfDNA for accurate determination of RAS and BRAF mutations using OncoBEAM liquid biopsy in metastatic colorectal cancer patients: Results of the real-world multicentric ColoBEAM study.

Alexandre Harlé,Celine Gavoille,Olivier Bouché,Meher Ben Abdelghani,Jérôme Edouard Plaza,Aurélien Lambert,Dominique Spaeth,Axelle Boudrant,François Ghiringhelli,Anne-Laure Villing,Christophe Borg,Marie Rouyer,Marie Husson,Pauline Gilson,Fabienne Polet,Frederick S. Jones,Daniel L. Edelstein,Florian Baumard,Julia Salleron,Jean-Louis Merlin

cfDNA for accurate determination of RAS and BRAF mutations using OncoBEAM liquid biopsy in metastatic colorectal cancer patients: Results of the real-world multicentric ColoBEAM study.

2019

3542Background: Determination of KRAS, NRAS (RAS) and BRAF mutations is a standard of care for the management of patients with metastatic colorectal cancer (mCRC). RAS mutations are well characteri...

Keywords:

Liquid biopsy
Colorectal cancer
Oncology
Pathology
Internal medicine
Medicine
standard of care
KRAS
Neuroblastoma RAS viral oncogene homolog

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations